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With cancer survival rate climbing up over the past three decades, quality of life for cancer patients has become an issue of major
concern. Oral health plays an important part in one’s overall quality of life. However, oral health status can be severely hampered
by side effects of cancer therapies including surgery, chemotherapy, radiotherapy, and hematopoietic stem cell transplantation.
Moreover, prevention and treatment of these complications are often overlooked in clinical practice. The present paper aims
at drawing health care professionals’ attention to oral complications associated with cancer therapy by giving a comprehensive
review. Brief comments on contemporary cancer therapies will be given first, followed by detailed description of oral complications
associated with cancer therapy. Finally, a summary of preventive strategies and treatment options for common oral complications
including oral mucositis, oral infections, xerostomia, and dysgeusia will be given.
1. Introduction
Cancer, from its initial diagnosis to the completion of its treat-
ment, is a heart-rending experience for many. It is a period of
great pressure and stress for not only the patients themselves
but also their families and friends. According to the United
States Cancer Statistics 2009, the National Program of Cancer
Registries, the ten ranking cancers by site in the Ameri-
can population (per 100,000 persons) are prostate (137.7),
breast (123.1), lung and bronchus (64.3), colon and rectum
(42.5), corpus and uterus, NOS (25.1), urinary bladder (20.5),
melanomas of the skin (19.4), non-Hodgkin’s lymphoma
(18.9), kidney and renal pelvis (15.7), and thyroid (13.2) [1].
TheAmerican Cancer Society has estimated that there will be
approximately 1,660,290 new cancer cases being diagnosed
in 2013. As the second leading cause of death in the United
States, preceded only by heart disease, cancer is expected
to take the lives of 580,350 Americans in the year of 2013,
that is, about 1600 deaths per day [2, 3]. Though the survival
statistics can vary significantly with the stage at which the
cancer is diagnosed as well as the cancer type itself, survival
rates continued to climb over the past years. In fact, the 5-
year relative survival rate for all cancers diagnosed from 2002
to 2008 is 68%, compared to 49% in 1975–1977 [3]. Coupled
with the ongoing advances in cancer detection and treatment
modalities, the future trend would entail increased likelihood
for dentists to encounter patients who are currently, or have
previously been, under cancer therapy.
Contemporary cancer treatment modalities commonly
include surgical resection, chemotherapy, radiotherapy, and
hematopoietic stem cell transplantation (HSCT), a form of
immunotherapy, either administered alone or used in com-
bination. Although the effectiveness of cancer treatment has
continued to improve over the past decades, collateral dam-
age to the head and neck structures is frequently encountered
as an unwanted consequence. Radio- and chemotherapy can
cause direct harm to the soft and hard tissue of the oral
structures, whereas their systemic toxicity can give rise to
indirect damages. These oral complications, be they acute or
chronic, may arise throughout and after cancer treatment and
often encompassmucositis, dysgeusia, and infectious diseases
[4]. Although literature has shown that the oral health
status in most cancer patients mirrors those of the general
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population, poorly restored dentition, moderate to advanced
periodontal disease, and other pathologies associated with
negligence of oral health care, the many oral complications as
sequelae of aggressive cancer treatment can greatly hamper
patients’ quality of life; this necessitates optimal oral health
care [5]. Maintaining oral health is essential in the preserva-
tion of daily functions, such as eating, verbal and nonverbal
communications, and the prevention of infectious diseases.
While the necessity of dental clearance is debatable and
empirical guidelines vary from center to center, assessment,
treatment, and prevention of any preexisting pathological
condition make up an important aspect of the overall treat-
ment outcome in cancer patients [6, 7]. Unfortunately, pri-
ority is often given to the more “life-threatening” condition
that is cancer, and administering oral care has become an
activity frequently neglected [8, 9]. Yet, it is the ethical and
medical/legal responsibility of all health care practitioners,
including professionals in the field of dentistry, to ensure that
the oral health status of patients undergoing cancer therapy
is thoroughly evaluated. Thus, it is the aim of this paper to
paint a detailed picture for dental professionals on the topic of
oncology related oral care. Cancer treatment modalities will
be introduced first and oral complications of cancer therapy
will be discussed. Some therapeutic alternatives thatmay help
to alleviate the painful and debilitating adverse effects will
also be presented.
2. Management of Malignancy
Treatment of malignancy is complex and often involves a
multidisciplinary approach. It is beyond the scope of this
paper to give an in-depth review of different types of cancer
therapy. Brief comments on cancer treatment modalities,
including surgery, chemotherapy, radiotherapy, and HSCT,
will be made to give a general picture of contemporary main-
stream cancer therapies.
Surgery has come a long way in the treatment of malig-
nancy and is still one of the most common methods in
managing primary solid tumors today [10]. In dentistry, the
impacts of surgical resection on patients’ lives are particularly
evident in the cases of oral and oropharyngeal cancers. Over
the past decades, advances in surgery have resulted in major
changes in surgical approaches to the mandibular areas and
cervical lymphnodes [11]. In addition, safer anesthesia, tumor
ablation via radiofrequency, and radiosurgery have opened
up many more options and alternatives for the professionals
in the effective management of the disease [12]. Combined
with advances in various reconstruction techniques, the func-
tional and aesthetic outcomes have been greatly improved in
cancer patients. Nowadays, survivors of head and neck can-
cers no longer have to live with severe functional disabilities
or aesthetic impairments that compromise their quality of life
[11].
Chemotherapeutic agents are drugs designed to have a
selective toxicity towards the tumor cells. Current chemo-
therapeutic agents are often cytostatic or cytotoxic in nature
to prevent the rapid division of the malignant cells and/or
destroy them in the process [13]. Unlike surgery and radiation
therapy, whose usages are limited to cancers confined to
specific areas of the body, the major advantage offered by
chemotherapy is the ability to target widespread ormetastatic
cancer [14]. Yet, even the most modern chemotherapeutic
agents are not without their shortcomings. Ironically, while
exploiting the tumor cells’ characteristic feature of shortened
cell cycle and having a selective toxicity design in mind, these
anticancer agents are not so “specific” as they also act upon
normal cells with a high turnover rate (accelerated cell cycle)
such as bonemarrow cells, hair follicle cells, and the epithelial
cells of the gastrointestinal tract [13, 15]. Some commondrugs
used in chemotherapy for oral cancer include 5-fluorouracil,
bleomycin, cisplatin, cyclophosphamide, methotrexate, and
vinblastine [16].
As one of the most effective forms of cancer treatment,
radiation therapy plays an indispensable role in the manage-
ment of many head and neck cancers as well as lymphomas.
The dose of ionizing radiation administered often depends
on factors such as the location of the malignancy, the type
of the malignancy, the sensitivity of the surrounding normal
tissues, and whether radiation is used as the sole treatment
option [17, 18]. Typically, for most head and neck cancer
patients, a dose of 2Gy per fraction is delivered once a day,
five days per week, over a five-to-seven-week period with a
total dosage of 64–70Gy [19]. The amount of radiation used
to treat malignant lymphomas is usually lower [17]. Although
the main aim of radiotherapy is to deliver a concentrated and
lethal dose of radiation to the solid tumor while at the same
timeminimizing the exposure of the surrounding tissues, the
salivary glands, oral mucosa, and jaws are inevitably covered
in the blast radius, resulting in a variety of problems within
the area [20].
HSCT, also known as bone marrow transplant, has
formed an important part of the treatment modalities for
many malignant diseases, acute and chronic leukemia, mye-
lodysplastic syndromes, myeloproliferative disorders, mul-
tiple myeloma, and non-Hodgkin’s lymphomas, as well as
a number of other nonmalignant diseases such as aplastic
anemia [21, 22]. For patients to undergo theHSCTprocedure,
they are required to partake in preoperative conditioning
which often involves the use of cyclophosphamide and total
body irradiation (TBI). The objective is to eradicate the
cancer and induce an immunosuppressive environment that
permits engraftments. Although HSCT can result in more
cures and remissions compared to alternative treatment, it
also tends to cause greater morbidity and mortality with the
mortality rates of less than 2% and 10% for some autologous
and allogeneic transplantations, respectively. With as much
as 40% of the advanced cancer patients dying from complica-
tions related to transplantation, further research is warranted
to determine the best ablative regimens for specific conditions
and reduce the toxicity of the preparative regimens [21].
3. Oral Complications of Cancer Therapy
3.1. General Considerations and Overview. Despite the en-
couraging evolvement in cancer management over the past
decades, one should bear in mind that current treatment
modalities do have the potential to result in debilitating
and sometimes life-threatening adverse effects that not only
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Figure 1: (a) Surgical resection involving part of themandible in a patient with rhabdomyosarcoma. (b) Limitedmouth opening after surgical
resection.
decrease the patients’ quality of life but also increase their
morbidity and mortality.
Oral complications associated with cancer therapy
encompass diseases such as stomatitis, infection, bleeding,
mucositis, pain, loss of function, and xerostomia [23]. The
mucosa, the periodontium, and the teeth are the three ana-
tomical sites most commonly associated with these compli-
cations [24]. Oral complications associated with specific
oncological therapy will be discussed in the following
sections.
3.2. Complications Associated with Surgery. The long-term
complications associated with the surgical treatment of oral
cancers are many; they range from functional limitations
on speech, mastication and swallowing, damages to the
cranial nerves and the resultant neurological problems,
chronic fistulas, and healing issues to aesthetic considerations
such as severe disfigurement and prosthetic rehabilitation;
taking these functional and aesthetic impairments, together
with their psychological implications, the patients’ long-term
quality of life could be hampered [25].
Surgical resection of cancers in the oral cavity can nega-
tively impact speech, mastication, and swallowing in a very
significant way. In general, surgical ablation that involves the
most anterior region of the tongue is often associatedwith sig-
nificant speech alteration, whereas ablation that incorporates
the posterior tongue affects swallowing [26–29]. With tumor
ablation and the subsequent loss of a significant portion of the
tongue, themanipulation and formation of the bolus (the oral
preparatory phase) and the transfer of bolus from the anterior
oral cavity to the posterior tonsillar area (the initiation of the
swallowing reflex) are severely restricted [30]. The situation
could be further complicated where surgical management
also involves the floor of mouth, maxilla, and mandible with
the adjacent tissues (Figure 1(a)); those are vital structures for
mastication. Resection of the maxilla or the mandible could
prove problematic for the patient during grinding as the sta-
ble and reproducible stomatognathic system relationships or
tooth-to-tooth contact is lost, resulting in diminished biting
force [30, 31]. Furthermore, combined with soft tissue bulk
and sensation loss, the ability of the patient to manipulate
food bolus to and fro fromocclusal table and its consolidation
before deglutition are impaired.Thus, the overall masticatory
efficiency, which encompasses manipulation, trituration, and
consolidation, being the result of synchronous interaction of
both hard and soft tissues, is drastically reduced [32].
Trismus, that is, limited mouth opening, is a common
complaint after oral cancer surgery (Figure 1(b)). Postoper-
ative healing, including fibrosis and scar contraction, often
results in restricted interocclusal opening of less than 35mm
between the maxillary and mandibular incisors. Procedures
thatmay lead to trismus commonly includemaxillary surgery
involving the origin of medial and lateral pterygoid muscles
from the pterygoid plates andmandibulectomy involving any
of the muscles of mastication (the temporalis insertion to
the coronoid process, the masseter insertion to the angle and
ramus, and the pterygoid insertions to the medial ramus and
condylar neck) [30]. Note that trismus could be exacerbated
by the fibrotic changes due to combination radiotherapy.
Additionally, the resection of primary tumor and lymph
nodes has put several cranial nerves at risk: spinal accessory
nerve, phrenic nerve, hypoglossal nerve, lingual nerve, vagus
nerve, sympathetic trunk, and marginal mandibular branch
of the facial nerve. The size of the tumor and its location
and the extent of the neck pathology often require the nerves
involved or in close association to be sacrificed. The issue
with access and certainty of satisfactory tumor removal can
compromise the integrity of the cranial nerves within the area
[30].
Fistula is another complication often associated with oral
oncologic surgeries.The risk of fistulas being developed often
depends on the general physical and nutritional status of the
patient, the incision design, and the tumor type and stage. Its
management is particularly difficult where radiation therapy
is also involved, as surgical wound closure is delayed due
to low oxygen tensions, vasculitis, endothelial fibrosis, and
reduced blood supply [25]. Fistulas generally occur 3-4 weeks
after surgery, but they can also develop as early as 1 week.
Persistent or chronic fistulas are those that remain present
1 month after the surgery. In addition, patients may present
with low grade fever, inflammation, and induration of the
skin flap under the area of dependant drainage. Prevention is
often the best treatment, but surgical excision and closure of
themucosa and skin are indicated where the problem persists
[25, 33].
The complex anatomy of the bone and associated muscle
attachments often require careful planning and placement
of plates and screws to stabilize bone segments and secure
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bone flaps in mandibular osteotomies and/or resection. Any
abusing of the reconstruction principles and overmanipu-
lation of the material, along with unbalanced masticatory
force, can result in hardware failure ranging from fracturing
of the plates, loosening of the screws, and mobility of the
mandibular segments to exposure of thematerial through the
overlying soft tissue and secondary infection [25]. Although
early treatment of the problem is preferred, surgical inter-
vention may be delayed due to adjunctive radiation therapy
which can compromise the wound healing; in which case,
hyperbaric oxygen treatments may improve the healing
abilities of the soft tissue overlying the hardware replacement
[33–35].
Appropriate prosthetic and functional rehabilitation,
which entails the reestablishment of a functional maxillo-
mandibular complex providing for an adequate dentition for
mastication with underlying bone support for facial features
and soft tissue for the restoration of speech and swallowing,
served as the desired endpoint for many patients. However,
such a feat may not always be feasible as many factors
play into this prosthetic problem. As noted by Kolokythas,
the issue is a multidisciplinary one; it may not always be
possible to convene all members of the treatment team to
discuss the treatment plan of the oral cancer patient prior
to resection. Thus, the plans for reconstruction may often
have to be formed postoperatively and may not be ideal.
Furthermore, the extent of the resection, several postsurgical
and radiation associated complications, may not allow for the
ideal rehabilitation. The patient’s compliance and financial
background may also be a barrier to reaching the final
restorative goal [25].
3.3. Complications Associated with Chemotherapy. Chemo-
therapeutic agents have gained a notorious reputation in
damaging not only the malignant cells but also the normal
tissue in the patient’s body. The level and the type of toxicity
of the treatment greatly depend on the overall immune status
of the patient prior to and during chemotherapy, the regimen
itself, the frequency and the dosage of the treatment, the route
of administration, and the type of tumor. In many patients,
these drugs can cause a number of oral complications includ-
ing mucositis, pain, infection, hemorrhage, xerostomia, and
neurologic and nutritional problems [14].
Oral mucositis (OM) is an iatrogenic condition of ery-
thematous inflammatory changes which tends to occur on
buccal and labial surfaces, the ventral surface of the tongue,
the floor of the mouth, and the soft palate of patients
receiving chemotherapy [36]. Its severity ranges from local-
ized (Figure 2) to generalized erythema (Figure 3) to frank
ulceration and hemorrhage [37]. The initial condition is
often described as a burning or tingling sensation making
the mouth hypersensitive to foods. And as the condition
progresses, eating, swallowing, and talking become increas-
ingly difficult [38]. In the more severe cases, OM can com-
promise the airway leading to anoxia-induced brain injury
and even death [39–41]. As a form of iatrogenic stomatitis,
mucositis usually starts off with aplasia 7–14 days after the
initiation of chemotherapy. Clinically, the earliest signmay be
characterized by leukoedema, appearing as a diffuse, poorly
Figure 2: Localized buccalmucositis in a patientwith osteosarcoma.
Figure 3: Generalized mucositis in a patient with acute myeloid
leukemia.
defined area of milky-white opalescence most noticeable on
the buccalmucosa, whichwill disappear upon stretching [14].
In the following 1-2 weeks, a loss of epithelial structure and
integrity is observed, and severe ulceration develops [42].
In general, OM can be assessed both clinically and with
subjective input from the patient. The World Health Orga-
nization (WHO) has also provided a useful grading scale that
combines both objective and subjective elements (Table 1)
[43]. Current literature’s reported incidence of OM is highly
variable, ranging from 75% to 99% [44, 45]. The current
working biophysical model of OM as proposed by Sonis
[40] involves 5 phases: initiation, upregulation and mes-
sage generation, amplification and signaling, ulceration, and
healing. Initiation involves direct irreversible and reversible
DNA damages and the generation of reactive oxygen species
via the chemotherapeutic agents. In the upregulation and
message generation phase, transcription factors (e.g., NF-𝜅B)
are activated, resulting in the production of messaging and
effector proteins including the proinflammatory cytokines
and enzymes. Positive feedback loops in phase III increase
cytokine production and thus signal amplification; apoptosis
and tissue injury ensue. In the ulcerative stage, clinically
evident erosions are detected; bacterial colonization and
additional proinflammatory cytokine secretions are also
involved. In due course, spontaneous healing occurs where
epithelial cells migrate to cover the ulcerations [40]. Several
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Table 1: WHO oral mucositis scale [43].
Grade Clinical presentation
0 Normal
1 Soreness with/without erythema
2 Ulceration and erythema
3 Ulceration and extensive erythema, patient cannotswallow solid food
4 Mucositis of such severity that feeding is not possible
chemotherapy agents have been associated with OM [46, 47].
A summary of these drugs is given in Table 2.
Chemotherapy-related oral infections, which account for
25–50% of the total infections, contribute significantly to the
morbidity and mortality in these patients [48]. Susceptible
areas include teeth, gingiva, salivary glands, and mucosa.
It should be noted that in the myelosuppressed patient the
cardinal signs of infection such as erythema and swelling are
not always present. Therefore, the more reliable indicators
such as fever, pain, and the appearance of lesions should be
used to closely monitor all suspected infections [14]. Com-
mon oral flora and opportunistic microorganisms include
coagulase-negative Staphylococci and Streptococci, Klebsiella
pneumonia, Pseudomonas aeruginosa, and Escherichia coli
[48–51]. It has been shown that pathogenic microorganisms
found subgingivally or in periradicular area may cause acute
exacerbations of preexisting periodontal or periradicular
infections when the granulocyte count dips below 1000/mm3
[49, 52].
Perhaps, themost dangerous complication in the realm of
infections comes from fungal species, most notably Candida
species [48, 49]. The mortality rate from systemic fungal
infections is much higher compared to other infections,
with the majority believed to have originated from the oral
cavity [49]. Clinically, fungal infections in the oral cavity can
manifest in several forms,with erythematous or pseudomem-
branous candidiasis being the most common. Erythematous
candidiasis presents itself as patchy or diffuse areas of ery-
thema, often occurring on the palate. Pseudomembranous
candidiasis appears as curd-like or patchy white lesions,
which can be rubbed off but will produce bleeding and
erosion in the tissue underneath. Also worth mentioning
is hyperplastic candidiasis, which resembles leukoplakia as
elevated white plaques that cannot be wiped off [53, 54].
Particularly troublesome is the chronic atrophic candidiasis,
which is often accompanied by angular cheilitis and denture
stomatitis. Angular cheilitis, an infection at the corner of the
mouth, may sometimes involve Staphylococcus species. Ill-
fitting denture bases, usually of themaxilla, can be a source of
chronic irritation and a reservoir for Candida albicans [14].
Viral infections frequently seen in patients undergoing
chemotherapy include the herpes simplex virus (HSV), vari-
cella zoster virus (VZV), and cytomegalovirus (CMV) [14].
Viral reactivity is not uncommon during periods ofmyeloim-
munosuppression, particularly with HSV infections. With
incidence of recurrent infection reported up to 48%, HSV
infected patients often report severe, painful, and prolonged
ulcerations atypical of those discovered in immunocompe-
tent hosts [55–57]. HSV recurrence typically appears 7–14
days after chemotherapy, and lesions can often be seen on
lips and keratinized mucosa as small cluster of vesicles that
rapidly ulcerate and coalesce [55, 58]. Fortunately, it is self-
limiting and resolves in 2 weeks. VZV infections, also known
as herpes zoster/shingles, can occur within the trigeminal
dermatome. Lesions can be seen on the face or intraorally
with the characteristic feature of halting abruptly at the
midline on the side of the respective trigeminal divisions
involved. Similar to HSV, VSV recurrence is confined to
keratinized mucosa and is shown to manifest several weeks
after the completion of chemotherapy, with widespread,
painful lesions lasting up to several weeks. Intraorally, CMV
infections may be seen as irregular pseudomembranous
ulcerations, coupled with common clinical manifestations
such as esophagitis, gastritis, colitis, hepatitis, pneumonia,
and retinitis. Furthermore, a fever may also be involved
but often resolves in 3–5 days. Dissemination of CMV in
immunosuppressed patients is often fatal [14].
Intraoral bleeding is another complication associated
with chemotherapy. The bleeding can be spontaneous, trau-
matically induced, or effect from existing pathology [59, 60].
It can also be the result of thrombocytopenia secondary to
hematopoietic tissues suppression. Laboratory tests should
be used to assess bleeding potential. Thrombocyte count and
bleeding time can give the dentist a decent picture of the
quantity, quality, and function of platelets.
3.4. Complications Associated with Radiotherapy. Orofacial
tissues that may be influenced by head and neck radiotherapy
include salivary glands, taste buds, mucousmembranes, bone
and teeth, the temporomandibular joint (TMJ), and related
musculatures. In general, complications from radiation ther-
apy are categorized into acute and chronic/late types. The
acute effects usually develop early in the radiation treatment
period and persist 2-3 weeks after completion of treatment,
whereas the late effects may become evident at any time after
treatment completion, ranging from weeks to years [61]. In
fact, it is shown that in 90% to 100% of the patients whose
radiation therapy covers the oral cavity some degree of oral
complication will always develop [62].
Xerostomia is perhaps the most commonly reported oral
sequela among patients receiving radiotherapy for head and
neck cancers. The effects of radiation on salivary glands
have been well documented. Ionizing radiation may cause
irreversible damage to glandular tissue and loss of salivary
fluid secretion; the gross architecture of the gland is slowly
replaced by ductal remnants and fibrous tissues with lympho-
cytes and plasma cells infiltration [63, 64]. The progressive
glandular atrophy and fibrosis and the reduction in salivary
outflow occur shortly after the initial exposure to radiation
and intensify thereafter [65]. Mantle, unilateral, and bilateral
fields of radiation are associated with a reduction of salivary
flow by 30% to 40%, 50% to 60%, and 80%, respectively.
For patients whose major salivary glands are in the radiation
fields, the prevalence of xerostomia is shown to range from
94% to 100% [66–68]. Clinically, the condition becomes
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Table 2: A summary of mucosatoxic chemotherapy agents (data adapted from Ko¨stler et al., 2001 [46], and Saadeh, 2005 [47]).
Category Drugs
Alkylating agents Busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, ifosfamide,lomustine, mechlorethamine, melphalan, oxaliplatin, procarbazine, and thiotepa
Anthracyclines Daunorubicin, doxorubicin, epirubicin, idarubicin, and mitoxantrone
Antimetabolites Capecitabine, cytarabine, floxuridine, 5-fluorouracil, hydroxyurea, 6-mercaptopurine, methotrexate,pemetrexed, and 6-thioguanine
Antitumor antibiotics Actinomycin d, amsacrine, bleomycin, mithramycin, mitomycin, and plicamycin
Natural products Etoposide, irinotecan, and streptozotocin
Taxanes Docetaxel and paclitaxel
Vinca alkaloids Vinblastine, vincristine, vindesine, and vinorelbine
Others Carboplatin, fludarabine, gemcitabine, interferons, interleukin-2, mitotane, and topotecan
apparent as saliva becomes “scant, sticky, and viscous.”
The patient may experience oral discomfort and pain. Fur-
thermore, dryness of themucosamay put the patient at risk of
oral infections and can lead to difficulties in speech, chewing,
and swallowing, which significantly affects their quality of
life [69, 70]. Reduced salivary outflow can also increase the
susceptibility to dental caries and compromise the mucosal
integrity [7]. It has been shown that xerostomia is associated
with as little as two or three doses of 2Gy each, whereas
doses greater than 30Gy can usually result in permanent
or semipermanent xerostomia [71, 72]. It is interesting to
note that a “compensatory” hypertrophy of the unirradiated
salivary gland may occur after a few months and up to 1 year
after therapy which may alleviate the condition; yet, if all the
major salivary glands are included in the field of radiation,
salivary function is expected to fall asmuch as 50–60%within
the first week [73, 74]. Thus, it is suggested that, if irradiation
of salivary tissues can be spared by patient positioning or
shielding, the resultant salivary gland dysfunction may be
reduced [75].
As taste is associated with salivary functions, it is not
uncommon to hear complaints of taste loss in relation
to xerostomia as a result of head and neck radiotherapy.
Dysgeusia can occur at a rapid rate and be exacerbated at
up to an accumulated dose of 30Gy, then the progress of
taste deteriorationwould slow down as perception for all four
tastes, that is, salty, sweet, sour, and bitter, approaches zero
[75]. In addition, microvilli damages brought about by the
radiation may cause secondary taste loss [75]. Fortunately,
the condition seems to be reversible. In the majority of the
cases, taste acuity is reported to be partially restored and fully
restored 20–60 days and 2–4 months after radiation therapy,
respectively [76]. However, there were reports of subjective
residual hypogeusia [75].
Perhaps, themost alarming andworrisome acute reaction
for patients receiving radiotherapy is the radiation-induced
mucositis.Thehigh turnover rate and low radiation resistance
of the mucosal cells within the oral cavity, pharynx, and
larynx make them susceptible to destruction from head and
neck fractionated external beam irradiation. In fact, the
literature shows that mucosal erythema could develop within
1 week of fractionated doses of, each, 2Gy per day [77].
The condition will intensify with continued treatment by
daily regimen doses of greater than 2Gy and large treat-
ment volumes such that almost all patients would develop
confluent mucositis by the third week [77]. Initially, the
erythema is the result of epithelium thinning and vascular
dilation, inflammation, and oedema of the submucosa [78].
As the therapy continues, however, the mucosa will become
denuded, ulcerated, and covered with a fibrinous exudate
[78]. There may also be bleeding. The patient is often
accompanied by symptoms of intense pain, dysphagia, and
odynophagia, which, in many cases, prevent oral intake and
necessitate the use of parenteral analgesics; as a result, not
only the patients’ quality of life but also the implementation
of the therapy itself is greatly affected [79]. Radiation-induced
mucositis usually persists 2-3 weeks after completion of
radiotherapy [77, 80]. About 90% to 95% of the patients
would show complete resolution by the 4th week [77].
It is now widely accepted that, through the generation
of free radicals, ionizing radiation can cause alteration of
the vascular elements in the bone within the irradiated
fields. Overtime, the irradiated area will show endothelial
cell death, hyalinization, thrombosis, and obliteration of
vessels; consequently, the periosteum and marrow spaces
will become fibrotic while the osteoblasts and osteocytes will
necrose [75]. The end result is an area described as being
hypovascular, hypocellular, and hypoxic, withminimal ability
to withstand trauma (e.g., dental extraction, alveoloplasty) or
to be repaired [81–83]. However, it should be noted that the
degree, progression, and irreversibility of these changes are
thought to be dose related [75]. In fact, osteoradionecrosis
(ORN) is not a common complication of radiotherapy, and
the incidence in the literature has been reported to range from
1% to 37.5% [61]. A representative 30-year retrospective study
of 830 patients showed a collective rate of only 8.2% [84].
There has also been report that the incidence of ORN is on a
decline over the past 20 years, which may be explained by the
advent of high-energy radiation sources [75, 85]. The ORN
contains a wide range of clinical presentations which vary
from a small stable asymptomatic region of exposed bone to
a full-scale ORN that is accompanied by severe pain, foul-
smelling necrotic bone of green-grey color, and suppuration
[61]. In general, elective oral surgical procedures such as
extractions or soft tissue surgeries are contraindicated within
the irradiated field [7].
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Currently, there is little data on the effects of ionizing radi-
ation on teeth. Results from literature appear to be conflicting
as to the differential decalcification rates between irradiated
and nonirradiated teeth. However, it is widely agreed that
the dental pulp of patients who received radiotherapy will
demonstrate reduced vascularity, accompanied by fibrosis
and atrophy [86]. Pulpal response to trauma, dental pro-
cedures, and bacterial assaults maybe compromised, but
tolerance to pain seems to increase.The secretorymechanism
of odontoblastsmay also be affected as excessive osteodentine
formation was observed in irradiated rats [87, 88]. With
regard to tooth development, the timing of exposure is
crucial; tooth bud may be destroyed if irradiation occurs
before significant calcification, while growthmay be retarded
and enamel and dentine irregularities result if exposure
happens during a later stage of development [86].
Under direct assault of the ionizing radiation, the TMJ
and the muscles of mastication may ultimately undergo
fibrosis and contracture resulting in trismus [89]. According
to the literature, about 5% to 38% of the patients develop
trismus after receiving radiation therapy for head and neck
cancer [90, 91]. Clinically, trismus manifests as the gradual
inability to open the mouth for normal functions; the onset
of reduced interincisal opening is generally noted at 9 weeks
after radiotherapy. A rate of 2.4% loss per month was
observed in the following 9 months, and a 32% reduction in
themean interincisal openingwas observed after 4 years [92].
Although speech articulation is not adversely affected, this
painless condition could make mastication and oral intake of
food particularly problematic.The implication is significantly
more profound in the case of denture wearers as they may
be unable to insert their prostheses and new ones cannot be
satisfactorily made due to restricted access and range of jaw
motions [75]. Oral hygiene is also severely compromised.
3.5. Complications Associated with HSCT. HSCT, once
viewed as experimental decades ago, has since advanced as
a customary treatment protocol for a variety of malignancies.
HSCT can be categorized into allogenic and autologous: the
former is where bone marrow is harvested from a histocom-
patible donor while the latter is from the patient’s own; both
are now regularly performed and considered standard of care
for selected malignancies [93]. The risk of oral complications
fromHSCT is comparable to that of conventional chemother-
apeutic treatment; patients receiving autologous transplant
exhibit possibly slightly higher risk while those undergoing
allogeneic graft may face cumbersome complications due to
the infusion of donor’s stem cells [94–96]. In general, patients
undergoing HSCT are at high risk of bacterial (including
those of periodontal origin), fungal (particularly Candida),
and viral (e.g., HSV, VZV, and CMV) infections [97–106].
Also, there has been report of hairy leukoplakia in human-
immunodeficiency-virus- (HIV-) negative HSCT patients
[107]. Potentially life-threatening complications from preex-
isting periodontitis have also been implicated from cultures
of atypical pathogenic organisms isolated from disease sites;
the importance of establishing healthy periodontal status
Figure 4: Soft tissue distortion in a patient with chronic GVHD.
before cancer therapy could not have been emphasized more
[108–110].
Perhaps, of particular concern is the graft versus host
disease (GVHD). GVHD is the most important complication
of allogeneic transplantation. It occurs via an immunological
reaction where the transplanted “graft” cells (donor lympho-
cytes) recognize the tissues of the “host” (the recipient) as
foreign. GVHD can be acute or chronic [111]. Acute form
of GVHD usually occurs within a few weeks of the trans-
plantation. It damages the skin, gut, and liver. Typical signs
and symptoms may include nausea, vomiting, abdominal
pain, diarrhea, bloody stool, and jaundice [21]. The main
risk factor is the major histocompatibility antigens (HLA)
mismatch; it has been shown that, if prophylaxis is not
provided, acuteGVHDcan affect almost every recipient [112].
Chronic GVHD may immediately follow the acute stage or
may occur several months later. It is associated with loss
of self-tolerance and symptomatically resembles scleroderma
or Sjo¨gren’s syndrome [113]. Chronic GVHD is character-
ized by bronchiolitis, keratoconjunctivitis sicca, esophageal
stricture, malabsorption, cholestasis, hematocytopenia, and
generalized immunosuppression [21]. The oral manifestation
ofGVHDvaries with the severity of the condition and is asso-
ciated with a spectrum of presentations. In general, clinical
or subclinical chronic GVHD exhibits features that include
mild oral mucosal erythema, desquamative gingivitis, loss
of lingual papillae, lichenoid hyperkeratosis, and xerostomia
(Figure 4), whereas acute GVHD patients may encounter
painful desquamation and ulcerative-pseudomembranous
reactions. Erythema, angular cheilitis, and lichenoid-like
changes have also been observed [111].
4. Present Practice and Therapeutic Options
Although priority is often given to the treatment of the
malignancy itself, focus should also be directed at prevention
and amelioration of complications that may occur as a result
of the disease and/or its treatment. A thorough head and
neck evaluation, oral soft and hard tissue examination, and
the associated intraoral radiographs are all essential parts of
the initial dental visit for cancer patients. The goal of such
visit is to remove and document any preexisting acute and
chronic pathological conditions, for example, periodontal
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and periapical pathology, residual cysts, and impacted or par-
tially erupted teeth. Through consultation with the patient’s
primary-care physician and revision of his/her medical sta-
tus, oral surgery, intermediate or definitive restorations, and
oral prophylaxis procedures may be performed safely, and
if required, under intravenous sedation and/or local/general
anesthesia [7]. It should be noted that evaluation, treatment,
and prevention of any preexisting oral and dental pathology
contribute significantly to the overall favourable treatment
outcome for cancer patients; for this reason, the patient’s oral
health status should be stabilized/optimized for minimally
predictable complications [7, 114].
In the following section, some therapeutic options for
the management of common oral complications of cancer
treatment are presented. Through this general guide, the
author of this paper sincerely hopes that general dental
practitioners can benefit from it and may find it useful in
ameliorating some of the painful oral complications of cancer
therapy.
4.1. Mucositis. Presently, there is no medication proven to
be able to successfully eliminate mucositis [4]. However,
painful symptoms can still be managed and oral discomfort
alleviated so as to improve the patient’s quality of life. The
current approach focuses on the management of pain and
the encouragement of eating, especially in chemotherapy-
induced mucositis [115]. One strategy on pain relief pertains
to the use of an oral solution mixture known as “Magic
Mouthwash;” it is composed of diphenhydramine, viscous
lidocaine, bismuth, subsalicylate, and corticosteroids [116].
It is said to relieve acute pain and reduce inflammation,
making oral consumption of food much easier. Yet, high-
grade mucositis pain is commonly relieved with potent
analgesic medications such as opioids [117]. Alternatively, a
number of recent studies have investigated the potential of
newer therapeutic interventions, in particular, concerning
the efficacy of growth factors and cytokines in curtailing
the development of high-grade mucositis and reducing the
duration of the lesions. Palifermin (Kepivance; Amgen,Thou-
sand Oaks, CA, USA), a recombinant human keratinocyte
growth factor vigorously researched, shows much promise
in reducing the frequency of high-grade (WHO grade 3
or 4) mucositis [118]. Furthermore, palifermin has been
demonstrated to decrease the duration of mucositis, thereby
lessening the use of parenteral nutrition and entailing higher
scores for physical and functional well-being [118]. In a
separate study, the beneficial effect of palifermin as preventive
therapy for mucositis has been confirmed [119]. Nevertheless,
the drug is not without its side effect; taste alteration in
patients treated with palifermin has been reported [120].
Other practical therapies for mucositis are also showing
promises, though evidence and data from the literature are
limited. One method widely used among oncologists is the
application of ice chips to the mouth every 30 minutes for
prevention and treatment of oral mucositis in patients under-
going chemotherapy.The rationale of oral cryotherapy is that,
through vasoconstriction, the release of chemotherapeutic
drugs to the mucosal epithelium is reduced [121]. Perhaps, an
effective preventivemeasure of recent interest is the use of low
level laser therapy (LLLT). Various studies have demonstrated
the potential benefits of LLLT in its ability to reduce the
rates of WHO severe grade mucositis [121, 122]. Other novel
methods and experimental approaches include a formulation
containing the amino acid L-glutamine and the hormone,
leptin; both have been shown to have a positive impact on
the development of mucositis [123–126].
4.2. Oral Infections. Often, cancer treatments can negatively
affect the patient’s immune system. With his/her immune
response suppressed, opportunistic infections can contribute
to significant morbidity and mortality.
4.2.1. Bacterial Infections. Normal oral flora comprises of a
variety of bacteria, some of which may become pathogenic
with immunosuppression. According to Rautemaa and col-
leagues, sepsis of unknown origin may possibly be the
result of oral infections (e.g., Viridans Streptococcus, Pre-
votella species, Fusobacterium,Actinobacillus actinomycetem-
comitans, and Actinomyces species) [127]. Nonetheless, the
infections are usually localized to oral mucosa and can be
treated with a combination of penicillin and metronidazole,
followed by routine dental procedures if necessary [4]. Given
the patient’s condition, meticulous oral hygiene practice is
paramount. Bacteriamay be removed from the teeth by gentle
brushingwith a soft bristle tooth brush and flossing. Onemay
consider using an antimicrobial mouthwash as an adjunct.
In the case where brushing becomes difficult (e.g., mucosal
damage), a chlorhexidine-containingmouthwash is generally
recommended [6].
4.2.2. Candidiasis. According to Lalla and colleagues, the
prevalence of oral fungal infection from all forms of cancer
therapy was about 7.5% before treatment, 40% during treat-
ment, and 30% after treatment [128]. Yet, a Cochrane meta-
analysis has concluded that there is currently insufficient
evidence from the literature to make a recommendation for
or against the treatment of oral candidiasis with antifun-
gal agents in patients undergoing cancer treatment [129].
Nevertheless, it is the responsibility of the general dental
practitioner to ease the patient’s suffering, and that entails
morbidity reduction and systemic infection prevention. It
should be noted that although topical antifungal agents are
commonly prescribed for their lower risk of side effects and
drug interactions, literature support of their efficacy is incon-
sistent [128]. According to the guidelines provided by the
Infectious Disease Society of America (IDSA), clotrimazole
troches and nystatin pastilles are the first line drugs for
mild oropharyngeal candidiasis [130]. However, they may be
difficult to apply in situations such as hyposalivation and/or
mucositis in which the experience can be traumatic; thus,
an alternate solution is to use nystatin rinses [128]. With the
high relapse rate of topical agents, one may also consider
systemic antifungal agents [131]. In fact, the IDSA guidelines
recommend the use of systemic fluconazole (100–200mg/day
for 2 weeks) (Diflucan; Pfizer Labs, New York, NY, USA) for
the management of moderate to severe infections [130]. In
fluconazole resistant cases, itraconazole capsules (200mg/day
for 2–4 weeks) or itraconazole oral solution (200mg/day for
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2 weeks) may also be considered [128]. As a second line drug,
posaconazole (Noxafil; Merck & CO., Whitehouse Station,
NJ, USA) is suggested by the IDSA [130]. In situations where
the disease becomes refractory, a broader spectrum drug of
a more potent nature such as voriconazole (Vfend; Pfizer
Labs, New York, NY, USA), caspofungin (Cancidas; Merck
& CO., Whitehouse Station, NJ, USA), and amphotericin B
(Fungizone; Bristol-Myers Squibb Co., Princeton, NJ, USA)
is suggested. Note that voriconazole has been reported to
be associated with severe photosensitivity, and possibly an
increased risk of skin cancer, whereas amphotericin B is
known for its systemic side effects, for example, high fever
[128, 130, 132].
Whereas the aforementioned modalities are all aimed at
treating oral candidiasis, the potential benefits of prophylaxis
should not be ignored, particularly in severely immuno-
suppressed and/or neutropenic patients. From a Cochrane
review, there is reasonably good evidence from randomized
controlled trials that drugs absorbed from the GI tract
prevent candidiasis in cancer patients [129]. A number of
studies have demonstrated the efficacy of prophylactic use
of fluconazole, itraconazole, posaconazole, and intravenous
micafungin (Mycamine; Astellas Pharma US, Inc., Deerfield,
IL, USA) in reducing the prevalence of all clinical fungal
infections during cancer therapy [128, 133–137]. Interestingly,
however, there has been little evidence from the literature
on the relative cost effectiveness of systemic versus topical
prophylaxis for oral fungal infections [129].
4.2.3. Viral Infections. HSV is quite prevalent in the general
population. In the majority of the cases, HSV infection
stems from latent viral reactivation. Current literature sug-
gests that immunosuppression due to chemotherapy is the
main contributive factor, with prevalence approaching 40%.
Neutropenic patients with hematological malignancies are
at the greatest risk, that is, 50%, during treatment [138].
Presently, acyclovir (Zovirax; GlaxoSmithKline Pharmaceu-
ticals, Research Triangle Park, NC, USA) and valacyclovir
(Valtrex; GlaxoSmithKline Pharmaceuticals, Research Trian-
gle Park, NC, USA) have both been shown to be equally
efficacious in prevention and treatment of HSV [139]. Oral
prophylaxis can be accomplished with acyclovir at the dose of
200–800mg thrice a day or valacyclovir at the dose of 500mg
twice a day [139–141]. During treatment, acyclovir may be
used intravenously at the dose of 5mg/kg every 8 hours or
perorally 200–400mg 3–5 times a day; on the other hand,
the unavailability of intravenous valacyclovir limits its use to
the oral dosing regimen of 500–1000 twice a day [139]. An
alternative is famciclovir (Famvir; Novartis Pharmaceuticals
Corp., East Hanover, NJ, USA). In case of drug resistance,
intravenous foscarnet (Foscavir; AstraZeneca, Wilmington,
NC,USA) and cidofovir (Vistide; Gilead Sciences, Inc., Foster
City, CA, USA) may be used [142].
Of particular concern is oral hairy leukoplakia (OHL),
a result of Epstein-Barr virus infection, commonly seen in
HIV infected individuals. However, OHL can also manifest
in immunocompromised patients (e.g., patients under cancer
treatment) who are HIV negative. Reports have shown that
OHL can occur in patients under chemotherapy for acute
myelogenous leukemia, acute lymphocytic leukemia, and
multiple myeloma, as well as in patients under corticosteroid
regimen for gastrointestinal stromal tumor [143–147]. At
present, there is no universal therapy for the management
of OHL; however, high dose oral valacyclovir may be used
safely and effectively [148]. Alternatively, topical treatment,
that is, 25% podophyllin resin alone or in combination with
5% topical acyclovir, and gentian violet could be considered
[149–151].
4.3. Xerostomia. Patients who have undergone head and
neck cancer radiotherapy tend to have long-term side effects
which are xerostomia and hyposalivation, resulting in further
complications such as increased caries incidence and loss
of taste [5]. It is advisable for the patient who has dry
mouth to take frequent sips of water (every 10 minutes) and
melt ice chips in mouth for comfort. Additionally, one may
consider the use of artificial saliva spray (e.g., Xerotin, Moi-
Stir, Salivart, Xero-Lube, Saliva Orthana) and mouth mois-
turizing gel (e.g., Biote`ne Oral Balance). The lips may well
be lubricated with petroleum jelly or a lanolin-containing
preparation (e.g., BioXtra moisturizing gel). Patients should
be cautioned against coffee, tea, soft drinks with caffeine, and
commercial mouth rinses with alcohol as they can dehydrate
the mouth. Alcohol-free mouth rinses (e.g., BioXtra alcohol-
free mouthrinse, Biote`ne mouthwash, and OralSeven mois-
turising mouthwash) are recommended. Residual salivary
gland activity and salivary flow ratemay be increased by saliva
stimulating tablets (SST) and medications like pilocarpine
(Salagen, 5mg, thrice a day), respectively. Finally, patients are
recommended to use sorbitol- or xylitol-based chewing gum
for salivary flow stimulation and caries arresting.
4.4. Dysgeusia. It is estimated that about 50% to 75% of
the cancer patients receiving chemotherapy, radiotherapy, or
both will suffer from distorted or impaired ability to taste
[152, 153]. While patients under radiation treatment tend to
suffer most from dysgeusia, its severity is highly correlated
to the cumulative radiation dose. Mild dysgeusia is generally
well tolerated; nevertheless, impaired ability to taste, which
affects appetite, reduces caloric intake, induces weight loss,
and hampers nutritional status, can exert great impact on the
patient’s quality of life [5]. At present, several strategies have
been proposed for the management of dysgeusia. Although
clinical efficacy of zinc supplementation has been quite
variable, its use has been suggested by several studies to ame-
liorate the debilitating effects of dysgeusia [154].The rationale
is such that zinc element may be structurally important in
the proteins responsible for regulating the taste bud pores
[5]. Additionally, one may also consider supplementing diet
with vitamin D as it was reported that patients suffering
from dysgeusia made improvement from it [155]. Sometimes,
dietary counselling may have more impact on long-term dys-
geusia and improve patient outcome [156, 157]. Several simple
methods have been utilized by nutritionists for symptomatic
patients [153]. Patients are advised to drink plenty of fluids
during meal, as such would enable the dissolution of taste
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components in the food and facilitate their translocation to
taste buds. Food should be chewed slowly and thoroughly to
release more flavours and stimulate saliva production; this
is especially crucial if the patient is also suffering from dry
mouth where saliva is important to taste. Patients should
also switch foods during meals to prevent adaptation of taste
receptors while taking care to maintain a balanced diet at the
same time [152].
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